Bos Sci's new BMS nets EU approval

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

Boston Scientific has received the CE mark for its Omega platinum chromium bare-metal stent (BMS) system, its third-generation coronary stenting technology.

The Natick, Mass.-based company said the stent incorporates its platinum chromium (PtCr) alloy designed for coronary stenting and is intended to provide interventional cardiologists with a BMS to treat patients with coronary artery disease. The Omega stent system is part of Boston Scientific's PtCr stent series, which includes the Taxus Element paclitaxel-eluting stent system and the Promus Element everolimus-eluting stent system.

Boston Scientific said it will immediately begin marketing the Omega stent system in the European Union and other CE mark countries.